Hepion (NASDAQ: HEPA) interim CEO linked to 1.25M-share open-market buy

Rhea-AI Filing Summary

Hepion Pharmaceuticals interim CEO Gary S. Stetz reported an indirect open-market purchase of 1,250,000 shares of common stock at $0.04 per share. The shares are held through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz account, and this filing shows total indirect holdings of 1,250,000 shares after the transaction.

Insider Trade Summary

Net Buyer: 1,250,000 shares ($50,000)

Net Buy 1 txn

Insider Stetz Gary S.

Role Interim CEO

Bought 1,250,000 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share	1,250,000	$0.04	$50K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 1,250,000 shares (Indirect, See Footnote)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 1,250,000 shares Purchase price: $0.04 per share Shares after transaction: 1,250,000 shares +1 more

4 metrics

Shares purchased 1,250,000 shares Open-market purchase of common stock

Purchase price $0.04 per share Price paid in the reported transaction

Shares after transaction 1,250,000 shares Indirect holdings following the purchase

Net buy direction 1,250,000 net-buy shares transactionSummary netBuySellShares/netBuySellDirection

Key Terms

open-market purchase, indirect ownership, 401K

3 terms

open-market purchase financial

"transaction_action: "open-market purchase" describes how the shares were acquired"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"direct_or_indirect: "I" and nature_of_ownership: "See Footnote" indicate indirect ownership"

401K financial

"Through Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz"

An employer-sponsored retirement savings plan in the United States that lets workers set aside part of their paycheck into investments with tax advantages; some plans also include employer matching contributions, which is like free money added to your savings. It matters to investors because 401(k) balances represent a large pool of household retirement assets that influence personal financial security, investor behavior, and long-term demand for stocks and bonds.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stetz Gary S.

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	04/21/2026		P		1,250,000	A	$0.04	1,250,000	I	See Footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Through Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz

	/s/ Gary S. Stetz	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Hepion Pharmaceuticals (HEPA) disclose on this Form 4?

Hepion Pharmaceuticals reported that interim CEO Gary S. Stetz was associated with an indirect open-market purchase of 1,250,000 common shares at $0.04 per share. The transaction reflects a net increase in his indirect holdings documented in this filing.

At what price were the Hepion (HEPA) shares bought in Gary Stetz’s Form 4 filing?

The Form 4 shows an open-market purchase price of $0.04 per share for Hepion common stock. With 1,250,000 shares acquired, the transaction represents a relatively small dollar amount but a sizable share count at this low trading price.

How many Hepion Pharmaceuticals (HEPA) shares does Gary Stetz hold after this transaction?

After the reported purchase, the Form 4 lists 1,250,000 common shares indirectly owned. This figure matches the transaction amount, indicating the filing shows this as his entire visible indirect position following the trade.

Is Gary Stetz’s Hepion (HEPA) share ownership direct or indirect in this Form 4?

The ownership is classified as indirect in the Form 4. A footnote explains the shares are held through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz, rather than in a direct personal brokerage account.

What does ‘open-market purchase’ mean in the Hepion (HEPA) Form 4 for Gary Stetz?

An open-market purchase indicates the shares were bought on the public market at prevailing prices, rather than granted as compensation. The Form 4 specifically labels this transaction as an open-market purchase of 1,250,000 Hepion common shares at $0.04 per share.

What role does Gary S. Stetz hold at Hepion Pharmaceuticals (HEPA) in this Form 4?

The Form 4 identifies Gary S. Stetz as both a director and an Interim CEO of Hepion Pharmaceuticals. His leadership position makes this open-market purchase a reportable insider transaction under SEC rules for company officers and directors.